For Release: August 31, 2012
Contact: Derik Hertel, 603-650-1211 or email@example.com
Merck CMO and Academic Leader to Speak at Geisel School of Medicine on How Industry and Academia Can Work Together
Hanover, N.H.—Michael Rosenblatt, MD, Executive Vice President and Chief Medical Officer at Merck & Co., will speak at the Geisel School of Medicine at Dartmouth on Thursday, Sept. 6, at noon in Borwell 658W, which is located on the school's Dartmouth-Hitchcock Medical Center campus. Dr. Rosenblatt, former dean of Tufts University School of Medicine, will bring his unique experience in academia, global health and industry to his presentation "Academia and Industry: How Can We Work Together?"
"We're very excited to have Dr. Rosenblatt come and speak with our faculty and students," says Dr. Wiley "Chip" Souba, dean of the Geisel School of Medicine. "His insights will be very valuable and timely given our growing research enterprise, and investment in translational research and innovation transfer as part of the 2020 Plan for Excellence."
Before serving in his current role at Merck, Dr. Rosenblatt was the Dean of Tufts University School of Medicine (2003-2009). Dr. Rosenblatt held the George R. Minot Professorship of Medicine at Harvard Medical School and Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center (BIDMC). He served as the President of BIDMC from 1999-2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for Academic Programs at CareGroup and BIDMC, and a founder of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and BIDMC.
Prior to that, Dr. Rosenblatt served as Director of the Harvard-MIT Division of Health Sciences and Technology. And earlier, he was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he co-led the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders.
In leading most of Merck's international research efforts, he established two major research institutes. He also headed Merck Research's worldwide University and Industry Relations Department.
Dr. Rosenblatt is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman's Award from Merck. Dr. Rosenblatt received his degree summa cum laude from Columbia and his MD magna cum laude from Harvard. His internship, residency and endocrinology training were all at Massachusetts General Hospital.
The Geisel School of Medicine at Dartmouth, founded in 1797, strives to improve the lives of the communities it serves through excellence in learning, discovery, and healing. The nation's fourth-oldest medical school, the Geisel School of Medicine has been home to many firsts in medical education, research and practice, including the discovery of the mechanism for how light resets biological clocks, creating the first multispecialty intensive care unit, the first comprehensive examination of U.S. health care cost variations (The Dartmouth Atlas), and helping establish the first Center for Health Care Delivery Science, which launched in 2010. As one of America's top medical schools, Dartmouth's Geisel School of Medicine is committed to training new generations of diverse physician leaders who will help solve our most vexing challenges in health care.
# # #